Figures & data
Table 1 Summary of Efficacy Outcomes for Ruxolitinib 1.5% Cream BID vs Vehicle BID (if Applicable) at Week 8 in Phase I–III Studies
Table 2 TEAEs for Ruxolitinib 1.5% Cream BID vs Vehicle BID (if Applicable) in Phase I–III Studies
Register now or learn more
Open access
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.